APA (7th ed.) Citation

Seufferlein, T., Lausser, L., Stein, A., Arnold, D., Prager, G., Kasper-Virchow, S., . . . Kestler, H. A. (2024). Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer—Results of the prospective multicenter PERMAD trial. PLoS ONE, 19(6), 1. https://doi.org/10.1371/journal.pone.0304324

Chicago Style (17th ed.) Citation

Seufferlein, Thomas, et al. "Prediction of Resistance to Bevacizumab Plus FOLFOX in Metastatic Colorectal Cancer—Results of the Prospective Multicenter PERMAD Trial." PLoS ONE 19, no. 6 (2024): 1. https://doi.org/10.1371/journal.pone.0304324.

MLA (9th ed.) Citation

Seufferlein, Thomas, et al. "Prediction of Resistance to Bevacizumab Plus FOLFOX in Metastatic Colorectal Cancer—Results of the Prospective Multicenter PERMAD Trial." PLoS ONE, vol. 19, no. 6, 2024, p. 1, https://doi.org/10.1371/journal.pone.0304324.